HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Calif. Carcinogenic Guideline Flexibility Vital - CIC

This article was originally published in The Rose Sheet

Executive Summary

Criteria for identifying chemicals for listing as "known to the state to cause cancer" are "more permissible" than higher regulatory bodies and should be based on the final judgment of the California Carcinogen Identification Committee, the group maintains.

You may also be interested in...



Diethanolamine Should Not Make Prop 65 List While Under FDA Review - CTFA

A safety ruling on diethanolamine by California EPA's Office of Environmental Health Hazard Assessment (OEHHA) would be "premature" while the cosmetic and OTC drug ingredient is undergoing FDA review, the Cosmetic, Toiletry and Fragrance Association asserts in April 6 comments to the agency.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel